Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Markets / Mark To Market/  Aurobindo remains on firm ground even as valuations reflect near-term gains
BackBack

Aurobindo remains on firm ground even as valuations reflect near-term gains

Aurobindo’s strategy has not only led to minimal price erosion in its base business but also enabled it to build a complex portfolio in the Injectables/Biosimilars/Inhaler space, analysts said

Aurobindo is amongst a few Indian pharmaceutical companies to have scaled up European business successfullyPremium
Aurobindo is amongst a few Indian pharmaceutical companies to have scaled up European business successfully

Aurobindo Pharma Ltd’s exclusive pact with Covaxx, the US-based company to develop Covid-19 vaccine opens large business scope. The vaccine once developed is meant for supplies in India, to the United Nations Children's Fund (UNICEF) agency and non-exclusive supplies to other emerging markets.

Aurobindo is a leading injectables and peptides manufacturer. The agreement thereby leverages Aurobindo’s existing development, commercial and manufacturing infrastructure for the first Multitope Peptide-based vaccine that utilizes normal refrigeration. With the vaccine being in the first phase of trials, the positives, however, may take 6-9 months to accrue, analysts said. The news has enthused the Street and the stock gained more than 2% on Thursday.

Meanwhile, Aurobindo’s prospects continue to see regular improvement. The company derives majority of its revenues from the US and Europe. The US revenues that account for almost half of consolidated revenue in Q2FY21 witnessed a 12.5% year-on-year growth. The rebound in Injectable sales has boosted investor confidence. In fact, the stock has gained close to 20% post September quarter results.

Injectables are difficult to manufacture and remain an important growth driver for the company’s US sales. Complex products see lower competition and hence lower price pressure and better margins. The company also has a diversified range of products and lower dependence on any specific product. This means the company’s growth remains insulated from rising competition in any particular product.

Aurobindo’s strategy has not only led to minimal price erosion in its base business but also enabled it to build a complex portfolio in the Injectables/Biosimilars/Inhaler space, wrote analysts at Motilal Oswal Financial Services in a note.

Further, the completed sale of its US subsidiary Natrol LLC in early December, at good valuations, will help Aurobindo attain net cash positive status too. The company had net debt of Rs1,445 crore (gross debt of Rs4,777 crore) as on 30 June. Notably, Aurobindo had acquired Natrol in December 2014 at valuations of 2 times enterprise value to sales (EV/sales). It has now divested the business at 3.5 times EV/sales with handsome gains.

Aurobindo is amongst a few Indian pharmaceutical companies to have scaled up European business successfully. The company’s ability to turnaround European acquisitions has helped. The transfer of manufacturing for acquired entities from Europe to India drives the gains. The European sales accounting for about fourth of consolidated too had rebounded 14.6% sequentially.

Overall Aurobindo’s forward prospects remain firm. The stock priced at Rs910.3 levels trades at 14.7 times one year forward earnings estimates and analyst believe most of the positives reflect in the valuations.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

ABOUT THE AUTHOR
Ujjval Jauhari
Ujjval Jauhari is a deputy editor at Mint, with over a decade of experience in newspapers and digital news platforms. He is skilled in storytelling, reporting, analysing and writing about stocks, investment ideas, markets, corporates and more. He is based in New Delhi.
Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 25 Dec 2020, 08:00 PM IST
Next Story footLogo
Recommended For You
GENIE RECOMMENDS

Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

Let’s get started
Switch to the Mint app for fast and personalized news - Get App